Literature DB >> 9786848

Crystal structure of monoclonal 6B5 Fab complexed with phencyclidine.

K Lim1, S M Owens, L Arnold, J C Sacchettini, D S Linthicum.   

Abstract

The crystal structure of monoclonal antibody (mAb) 6B5 Fab fragment complexed with 1-(1-phenylcyclohexyl)piperidine (PCP or phencyclidine) was determined at 2.2-A resolution. 6B5 was originally produced from a mouse immunized with a phencyclidine analogue hapten 5-[N-(1'phenylcyclohexyl)amino]pentanoic acid conjugated to bovine serum albumin. This mAb was selected for further study because of its high affinity (Kd = 2 x 10(-9) M/liter) for PCP and usefulness in reversing PCP-induced central nervous system toxicity in laboratory animals. The dominant feature of the 6B5 Fab.PCP complex is the deep binding site and hydrophobic nature of the interaction. The ligand binding pocket of 6B5 Fab has numerous aromatic side chains, as compared with other known Fab structures. The most notable feature of the binding site is a Trp at position 97H (H-chain), and the side chain of this residue appears to act as a hydrophobic umbrella on the ligand in the antigen binding pocket. There are only two other known Fabs found with a Trp at the 97H position in complementarity determining region (CDR) H3, but they do not play a major role in the interaction with their respective antigens; in both Fab TE33 and R6.5 the Trp 97H side chain is positioned away from the bound antigen. Comparison of the CDR residues of 6B5 with other Fab structures with similar CDR sizes and amino acid compositions reveals a number of important patterns of residue substitutions that appear to be critical for specific PCP ligand interactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9786848     DOI: 10.1074/jbc.273.44.28576

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Structure of anti-FLAG M2 Fab domain and its use in the stabilization of engineered membrane proteins.

Authors:  Tarmo P Roosild; Samantha Castronovo; Senyon Choe
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-08-18

Review 2.  Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Authors:  Eric C Peterson; W Brooks Gentry; S Michael Owens
Journal:  Adv Pharmacol       Date:  2014

3.  Antibodies as a model system for comparative model refinement.

Authors:  Benjamin D Sellers; Jerome P Nilmeier; Matthew P Jacobson
Journal:  Proteins       Date:  2010-08-15

4.  Crystal structures of a therapeutic single chain antibody in complex with two drugs of abuse-Methamphetamine and 3,4-methylenedioxymethamphetamine.

Authors:  Reha Celikel; Eric C Peterson; S Michael Owens; Kottayil I Varughese
Journal:  Protein Sci       Date:  2009-11       Impact factor: 6.725

5.  Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.

Authors:  H Marie Lacy; Melinda G Gunnell; Elizabeth M Laurenzana; S Michael Owens
Journal:  Int Immunopharmacol       Date:  2007-10-23       Impact factor: 4.932

6.  Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays.

Authors:  Matthew D Krasowski; Mohamed G Siam; Manisha Iyer; Anthony F Pizon; Spiros Giannoutsos; Sean Ekins
Journal:  Clin Chem       Date:  2009-04-02       Impact factor: 8.327

7.  Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays.

Authors:  Matthew D Krasowski; Mohamed G Siam; Manisha Iyer; Sean Ekins
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

8.  Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.

Authors:  Matthew D Krasowski; Anthony F Pizon; Mohamed G Siam; Spiros Giannoutsos; Manisha Iyer; Sean Ekins
Journal:  BMC Emerg Med       Date:  2009-04-28

Review 9.  Therapeutic applications of monoclonal antibodies.

Authors:  Mitchell Berger; Vidya Shankar; Abbas Vafai
Journal:  Am J Med Sci       Date:  2002-07       Impact factor: 2.378

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.